Boston Scientific Weighs Endosurgery IPO, Other Asset Sales To Repay Debt
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is evaluating the potential sale of a minority equity stake in its endosurgery group and may consider additional asset sales to help accelerate repayment of debt incurred in its purchase of Guidant nearly a year ago, the company says
You may also be interested in...
Boston Scientific Sells Fluid Management, Venous Access Units
Private equity firm Avista Capital Partners plans to operate Boston Scientific's combined fluid management and venous access units as a stand-alone company after acquiring the businesses for $425 million on Dec. 13
Boston Scientific Sells Fluid Management, Venous Access Units
Private equity firm Avista Capital Partners plans to operate Boston Scientific's combined fluid management and venous access units as a stand-alone company after acquiring the businesses for $425 million on Dec. 13
Boston Scientific Cuts Workforce By 13% To Help Save In ’08 H
Boston Scientific will reduce its head count by 2,300 and consolidate certain business units as part of a broader restructuring plan aimed at saving an estimated $475 million to $525 million in 2008, the firm announced Oct. 17